Therapeutic potential of neuropeptide Y (NPY) receptor ligands

Neuropeptide Y (NPY) is widely distributed in the human body and contributes to a vast number of physiological processes. Since its discovery, NPY has been implicated in metabolic regulation and, although interest in its role in central mechanisms related to food intake and obesity has somewhat diminished, the topic remains a strong focus of research concerning NPY signalling. In addition, a number of other uses for modulators of NPY receptors have been implied in a range of diseases, although the development of NPY receptor ligands has been slow, with no clinically approved receptor therapeutics currently available. Nevertheless, several interesting small molecule compounds, notably Y2 receptor antagonists, have been published recently, fueling optimism in the field. Herein we review the role of NPY in the pathophysiology of a number of diseases and highlight instances where NPY receptor signalling systems are attractive therapeutic targets.

[1]  R. Quirion,et al.  Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5). , 2000, Canadian journal of physiology and pharmacology.

[2]  J. Nurnberger,et al.  Neuropeptide Y receptor genes are associated with alcohol dependence, alcohol withdrawal phenotypes, and cocaine dependence. , 2008, Alcoholism, clinical and experimental research.

[3]  P. Widdowson,et al.  Regulation of Neuropeptide Y Release by Neuropeptide Y Receptor Ligands and Calcium Channel Antagonists in Hypothalamic Slices , 1999, Journal of neurochemistry.

[4]  W. Kraus,et al.  Neuropeptide Y Gene Polymorphisms Confer Risk of Early-Onset Atherosclerosis , 2009, PLoS genetics.

[5]  L.,et al.  Isolation and characterization of a new pancreatic polypeptide hormone. , 1975, The Journal of biological chemistry.

[6]  P. Mermelstein,et al.  Calcitonin Gene-Related Peptide Regulates Expression of Neurokinin1 Receptors by Rat Spinal Neurons , 2003, The Journal of Neuroscience.

[7]  Zhang Jy,et al.  Effects of neuropeptide Y , 1993 .

[8]  R. Quirion,et al.  Neuropeptide Y (NPY) Y2 receptors mediate behaviour in two animal models of anxiety: evidence from Y2 receptor knockout mice , 2003, Behavioural Brain Research.

[9]  Jason U Tilan,et al.  Chronic Stress, Combined with a High‐Fat/High‐Sugar Diet, Shifts Sympathetic Signaling toward Neuropeptide Y and Leads to Obesity and the Metabolic Syndrome , 2008, Annals of the New York Academy of Sciences.

[10]  T. Adrian,et al.  Peptide YY abnormalities in gastrointestinal diseases. , 1986, Gastroenterology.

[11]  G. Ordway,et al.  Reduced Neuropeptide Y Concentrations in Suicide Brain , 1992, Journal of neurochemistry.

[12]  D. Tracey,et al.  Peripheral hyperalgesia in experimental neuropathy: exacerbation by neuropeptide Y , 1995, Brain Research.

[13]  Motonao Nakamura,et al.  Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  G. Kaur,et al.  On the intrinsic regulation of neuropeptide Y release in the mammalian suprachiasmatic nucleus circadian clock , 2010, The European journal of neuroscience.

[15]  D. Erlinge,et al.  Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells: cooperation with noradrenaline and ATP , 1994, Regulatory Peptides.

[16]  M. Ando,et al.  Modulation of neuropeptide Y receptors for the treatment of obesity , 2009, Expert opinion on therapeutic patents.

[17]  H. Herzog,et al.  Evidence from knockout mice for distinct implications of neuropeptide-Y Y2 and Y4 receptors in the circadian control of locomotion, exploration, water and food intake , 2009, Neuropeptides.

[18]  R. Rimondini,et al.  Blockade of central neuropeptide Y (NPY) Y2 receptors reduces ethanol self-administration in rats , 2002, Neuroscience Letters.

[19]  M. Dickie,et al.  Obese, a new mutation in the house mouse. , 1950, The Journal of heredity.

[20]  C. Ehlers,et al.  The effects of social isolation on neuropeptide Y levels, exploratory and anxiety-related behaviors in rats , 2006, Pharmacology Biochemistry and Behavior.

[21]  H. Cox,et al.  Neuropeptide Y, Y1, Y2 and Y4 receptors mediate Y agonist responses in isolated human colon mucosa , 2002, British journal of pharmacology.

[22]  C. Wahlestedt,et al.  Neuropeptide Y (NPY) and the central nervous system: Distribution effects and possible relationship to neurological and psychiatric disorders , 1989, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[23]  R. Rimondini,et al.  Suppression of ethanol self-administration by the neuropeptide Y (NPY) Y2 receptor antagonist BIIE0246: evidence for sensitization in rats with a history of dependence , 2005, Neuroscience Letters.

[24]  S. Bloom,et al.  The therapeutic potential of gut hormone peptide YY3-36 in the treatment of obesity , 2005, Expert opinion on investigational drugs.

[25]  R. Palmiter,et al.  Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y , 1996, Nature.

[26]  M. Michel Neuropeptide Y Receptors , 2008 .

[27]  E. Potter,et al.  Role of neuropeptide Y Y2 receptors in modulation of cardiac parasympathetic neurotransmission , 2002, Regulatory Peptides.

[28]  Jason U Tilan,et al.  Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome , 2007, Nature Medicine.

[29]  A. Steiger,et al.  Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men , 2000, Neuropharmacology.

[30]  J. Eisman,et al.  Greater Bone Formation of Y2 Knockout Mice Is Associated with Increased Osteoprogenitor Numbers and Altered Y1 Receptor Expression* , 2007, Journal of Biological Chemistry.

[31]  T. Hökfelt,et al.  Neuropeptide tyrosine and pain. , 2007, Trends in pharmacological sciences.

[32]  Roseanne Norris,et al.  The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists. , 2009, Bioorganic & medicinal chemistry letters.

[33]  S. Whitebread,et al.  A receptor subtype involved in neuropeptide-Y-induced food intake , 1996, Nature.

[34]  J. Shine,et al.  Cloned human neuropeptide Y receptor couples to two different second messenger systems. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[35]  V. Mutt,et al.  Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides , 1980, Nature.

[36]  P. Ernfors,et al.  Assessment of ethanol consumption and water drinking by NPY Y2 receptor knockout mice , 2004, Peptides.

[37]  F. Sallee,et al.  Relevance of neuropeptide Y (NPY) in psychiatry. , 2007, Current topics in medicinal chemistry.

[38]  H. Cox Neuropeptide Y receptors; antisecretory control of intestinal epithelial function , 2007, Autonomic Neuroscience.

[39]  S. Tufik,et al.  Orexin activation precedes increased NPY expression, hyperphagia, and metabolic changes in response to sleep deprivation. , 2010, American journal of physiology. Endocrinology and metabolism.

[40]  G. Glavin,et al.  Effects of neuropeptide Y and [Leu31,Pro34] neuropeptide Y on experimental gastric lesion formation and gastric secretion in the rat. , 1993, The Journal of pharmacology and experimental therapeutics.

[41]  L. Niskanen,et al.  Leucine7 to proline7 polymorphism in prepro-NPY gene and femoral neck bone mineral density in postmenopausal women. , 2004, Bone.

[42]  B. McDermott,et al.  Evidence for Y1 and Y2 subtypes of neuropeptide Y receptors linked to opposing postjunctional effects observed in rat cardiac myocytes. , 1997, European journal of pharmacology.

[43]  K. Kodukula,et al.  Cloning and Functional Expression of a cDNA Encoding a Human Type 2 Neuropeptide Y Receptor (*) , 1995, The Journal of Biological Chemistry.

[44]  J. Eisman,et al.  Hypothalamic Regulation of Cortical Bone Mass: Opposing Activity of Y2 Receptor and Leptin Pathways , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[45]  P. Ernfors,et al.  Reduced antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor , 2001, Nature.

[46]  C. Wahlestedt,et al.  Selective and Brain Penetrant Neuropeptide Y Y2 Receptor Antagonists Discovered by Whole-Cell High-Throughput Screening , 2010, Molecular Pharmacology.

[47]  J. Eisman,et al.  Novel Role of Y1 Receptors in the Coordinated Regulation of Bone and Energy Homeostasis* , 2007, Journal of Biological Chemistry.

[48]  P. Arner,et al.  Common neuropeptide Y2 receptor gene variant is protective against obesity among Swedish men , 2006, International Journal of Obesity.

[49]  Yihai Cao,et al.  Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M. Cha,et al.  Modulation of Neuropathic Pain by Galanin and Neuropeptide Y at the Level of the Medulla in Rats , 2009, The International journal of neuroscience.

[51]  R. Palmiter,et al.  Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[52]  R. Barker,et al.  Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis , 2011, Hippocampus.

[53]  D. Smiley,et al.  The Neuropeptide Y Y1 Antagonist, 1229U91, A Potent Agonist for the Human Pancreatic Polypeptide-Preferring (NPY Y4) Receptor , 1998, Peptides.

[54]  D. Larhammar,et al.  Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. , 1992, The Journal of biological chemistry.

[55]  T. Branchek,et al.  Cloning and Functional Expression of a Human Y4 Subtype Receptor for Pancreatic Polypeptide, Neuropeptide Y, and Peptide YY (*) , 1995, The Journal of Biological Chemistry.

[56]  T. Adrian,et al.  NEUROPEPTIDE Y IN PHAEOCHROMOCYTOMAS AND GANGLIONEUROBLASTOMAS , 1983, The Lancet.

[57]  Herbert Herzog,et al.  Y4 receptor knockout rescues fertility in ob/ob mice. , 2002, Genes & development.

[58]  D. Mcfadden,et al.  NPY family of hormones: clinical relevance and potential use in gastrointestinal disease. , 2007, Current topics in medicinal chemistry.

[59]  J. Kitlinska,et al.  Neuropeptide Y (NPY) in neuroblastoma: Effect on growth and vascularization , 2007, Peptides.

[60]  R. Joehl,et al.  Pancreatic polypeptide inhibits amylase release by rat pancreatic acini. , 1986, The Journal of surgical research.

[61]  E. Arenas,et al.  Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor , 1999, Nature Medicine.

[62]  G. Sperk,et al.  Neuropeptide Y in the dentate gyrus. , 2007, Progress in brain research.

[63]  W. T. Chen,et al.  Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. , 1998, Circulation research.

[64]  A. Zengin,et al.  Neuropeptide Y and sex hormone interactions in humoral and neuronal regulation of bone and fat , 2010, Trends in Endocrinology & Metabolism.

[65]  V. Mutt,et al.  Neuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide , 1982, Nature.

[66]  N. Tamamaki,et al.  Mechanisms of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Inhibition of Identified Green Fluorescent Protein-Expressing GABA Neurons in the Hypothalamic Neuroendocrine Arcuate Nucleus , 2005, The Journal of Neuroscience.

[67]  Rachel L. Batterham,et al.  Gut hormone PYY3-36 physiologically inhibits food intake , 2002, Nature.

[68]  R. Rimondini,et al.  Differential expression of NPY and its receptors in alcohol-preferring AA and alcohol-avoiding ANA rats. , 2001, Alcoholism, clinical and experimental research.

[69]  A. Pitkänen,et al.  Neuropeptide Y overexpression using recombinant adenoassociated viral vectors , 2009, Neurotherapeutics.

[70]  X. T. Zhao,et al.  Fat-induced ileal brake in the dog depends on peptide YY. , 1996, Gastroenterology.

[71]  L. Grundemar Multiple receptors and multiple actions , 1997 .

[72]  C. Wahlestedt,et al.  Evidence for different pre- and post-junctional receptors for neuropeptide Y and related peptides , 1986, Regulatory Peptides.

[73]  A. Sollevi,et al.  Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. , 1990, Cardiovascular research.

[74]  A. Beck‐Sickinger,et al.  First selective agonist of the neuropeptide Y1‐receptor with reduced size , 2009, Journal of peptide science : an official publication of the European Peptide Society.

[75]  G. Greeley,et al.  Characterization of Two Novel Proabsorptive Peptide YY Analogs, BIM-43073D and BIM-43004C , 2004, Digestive Diseases and Sciences.

[76]  D. Allison,et al.  PYY3‐36 as an anti‐obesity drug target , 2005, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[77]  D. Reis,et al.  Identification of cultured cells selectively expressing Y1-, Y2-, or Y3-type receptors for neuropeptide Y/peptide YY. , 1992, Life sciences.

[78]  M. Devor,et al.  Chemically Mediated Cross-Excitation in Rat Dorsal Root Ganglia , 1996, The Journal of Neuroscience.

[79]  J. Polak,et al.  NEUROPEPTIDE TYROSINE (NPY)—A MAJOR CARDIAC NEUROPEPTIDE , 1983, The Lancet.

[80]  Bengt Långström,et al.  Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. , 2006, Cell metabolism.

[81]  P. Mantyh Neurobiology of substance P and the NK1 receptor. , 2002, The Journal of clinical psychiatry.

[82]  C. Strader,et al.  Cloning and Expression of a Novel Neuropeptide Y Receptor* , 1996, The Journal of Biological Chemistry.

[83]  G. Koob,et al.  Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. , 1993, Science.

[84]  R. Murison,et al.  Intracerebroventricular neuropeptide Y protects against stress-induced gastric erosion in the rat. , 1987, European journal of pharmacology.

[85]  T. Hökfelt,et al.  The neuropeptide tyrosine Y1R is expressed in interneurons and projection neurons in the dorsal horn and area X of the rat spinal cord , 2006, Neuroscience.

[86]  M. Michel Neuropeptide Y and Drug Development , 1998 .

[87]  Ruihua Shi,et al.  Correlation of Gut Hormones with Irritable Bowel Syndrome , 2008, Digestion.

[88]  Yun Feng,et al.  Molecular Characterization of a Second Mouse Pancreatic Polypeptide Receptor and Its Inactivated Human Homologue* , 1996, The Journal of Biological Chemistry.

[89]  H. Herzog,et al.  NPY regulation of bone remodelling , 2009, Neuropeptides.

[90]  T. Hökfelt,et al.  Distribution of neuropeptide Y Y1 receptors in rodent peripheral tissues , 2002, The Journal of comparative neurology.

[91]  W. Colmers,et al.  Opioid-like actions of neuropeptide Y in rat substantia gelatinosa: Y1 suppression of inhibition and Y2 suppression of excitation. , 2004, Journal of neurophysiology.

[92]  T. Hökfelt,et al.  Neuropeptide Y2 receptor protein is present in peptidergic and nonpeptidergic primary sensory neurons of the mouse , 2005, The Journal of comparative neurology.

[93]  J. P. Hobson,et al.  Neuropeptide Y induces migration , proliferation , and tube formation of endothelial cells bimodally via Y 1 , Y 2 , and Y 5 receptors , 2006 .

[94]  G. Ronnett,et al.  Neuropeptide Y functions as a neuroproliferative factor , 2001, Nature.

[95]  P. Ernfors,et al.  Attenuation of acute experimental colitis by preventing NPY Y1 receptor signaling. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[96]  S. Southwick,et al.  A functional neuropeptide Y Leu7Pro polymorphism associated with alcohol dependence in a large population sample from the United States. , 2002, Archives of general psychiatry.

[97]  M. Parmentier,et al.  Agonist and antagonist activities on human NPFF2 receptors of the NPY ligands GR231118 and BIBP3226 , 2001, British journal of pharmacology.

[98]  C. Wahlestedt,et al.  Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. , 1985, The Journal of pharmacology and experimental therapeutics.

[99]  M. Heilig The NPY system in stress, anxiety and depression , 2004, Neuropeptides.

[100]  H. Akiho,et al.  Inactivation of a Novel Neuropeptide Y/Peptide YY Receptor Gene in Primate Species* , 1996, The Journal of Biological Chemistry.

[101]  D. Reis,et al.  Neuropeptide Y Receptor Subtypes, Y1 and Y2 , 1990, Annals of the New York Academy of Sciences.

[102]  P. Magni,et al.  Relevance of the neuropeptide Y system in the biology of cancer progression. , 2007, Current topics in medicinal chemistry.

[103]  Jason U Tilan,et al.  Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. , 2005, Cancer research.

[104]  T. Branchek,et al.  Expression Cloning and Pharmacological Characterization of a Human Hippocampal Neuropeptide Y/Peptide YY Y2 Receptor Subtype (*) , 1995, The Journal of Biological Chemistry.

[105]  R. Palmiter,et al.  Neuropeptide Y ( NPY ) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y 5 receptors , 2000 .

[106]  R. Harris,et al.  Patterns of gene expression are altered in the frontal and motor cortices of human alcoholics , 2002, Journal of neurochemistry.

[107]  B. McDermott,et al.  NPY and cardiac diseases. , 2007, Current topics in medicinal chemistry.

[108]  X. S. Fu,et al.  [Effects of neuropeptide Y]. , 1993, Sheng li ke xue jin zhan [Progress in physiology].

[109]  C. Jayasena,et al.  Gut Hormones: A Weight Off Your Mind , 2008, Journal of neuroendocrinology.

[110]  N. Decarolis,et al.  Hippocampal neurogenesis as a target for the treatment of mental illness: A critical evaluation , 2010, Neuropharmacology.

[111]  R. Eglen,et al.  Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y-Y1 receptor antagonist. , 1995, The Journal of pharmacology and experimental therapeutics.

[112]  G. Schnorrenberg,et al.  BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. , 1999, European journal of pharmacology.

[113]  G. Cornelissen,et al.  Neuropeptide chronomics in clinically healthy young adults: circaoctohoran and circadian patterns , 2004, Peptides.

[114]  G. Sperk,et al.  Anticonvulsant effects and behavioural outcomes of rAAV serotype 1 vector-mediated neuropeptide Y overexpression in rat hippocampus , 2010, Gene Therapy.

[115]  Arndt F Schilling,et al.  Leptin Inhibits Bone Formation through a Hypothalamic Relay A Central Control of Bone Mass , 2000, Cell.

[116]  G. Thomas,et al.  Hypothalamic Y2 receptors regulate bone formation. , 2002, The Journal of clinical investigation.

[117]  S. Herness,et al.  The neuropeptides CCK and NPY and the changing view of cell-to-cell communication in the taste bud , 2009, Physiology & Behavior.

[118]  R. Palmiter,et al.  Role of the Y5 neuropeptide Y receptor in feeding and obesity , 1998, Nature Medicine.

[119]  J. Bue-Valleskey,et al.  The role of neuropeptide Y in the antiobesity action of the obese gene product , 1995, Nature.

[120]  P. Bonaventure,et al.  In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor , 2010, Psychopharmacology.

[121]  G. Aponte,et al.  Meal‐induced peptide tyrosine tyrosine inhibition of pancreatic secretion in the rat , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.